Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer.

@article{Qvortrup2010AdditionOS,
  title={Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer.},
  author={Camilla Qvortrup and Benny Vittrup Jensen and Trine Lembrecht Jorgensen and Dorte Nielsen and Jon Kroll Bjerregaard and Per Pfeiffer},
  journal={Acta oncologica},
  year={2010},
  volume={49 6},
  pages={833-6}
}
UNLABELLED Results of continuous sunitinib, in combination with cetuximab and irinotecan every other week (SIC) for compassionate use in heavily pre-treated patients with mCRC are presented. PATIENTS AND METHODS Patients with mCRC resistant to oxaliplatin, irinotecan, 5-FU and cetuximab received SIC at two Danish oncologic departments. The regimen consisted of sunitinib given as a continuous-dosing in combination with cetuximab and irinotecan every other week (CetIri). The first six patients… CONTINUE READING